AlphAIAlphAI — Financial news for AI agents
investing.com$GKOS

Glaukos stock price target raised to $225 by Mizuho on Epioxa sales

Mizuho raised its price target for Glaukos (GKOS) to $225, citing strong revenue of $211M, beating estimates. Epioxa sales were $53M, above Mizuho's $18M estimate. The company raised 2026 guidance to $775M-$785M and projected $1B for 2027. GKOS shares are near a 52-week high, up 135% over the past year.

Original reporting
investing.com
Published Oct 29, 2026, 10:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 10:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$GKOS
Bullish
high confidence
Mentioned
$GKOS
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GKOSBullishHigh
01

Why it matters

The earnings beat and guidance raise provide a fresh catalyst for short‑term price appreciation.

02

Market read

Strong earnings and analyst upgrades make GKOS a notable short‑term mover in the health‑care sector.

03

What to watch

Potential reimbursement risk if payer policies change after J‑Code implementation.

Relevance 8/10Novelty 8/10Timing: today

Background

Glaukos (GKOS) reported Q3 results that exceeded expectations and received upgraded price targets from Mizuho and Truist.

Company-level read

Ticker impact

$GKOSBullishHigh confidence
Context

Mizuho raised its price target to $225 and reported Q3 revenue of $211M beating estimates, while raising full-year guidance to $775‑$785M.

Expected impact

likely upward pressure as the market prices in the earnings beat and higher guidance

Evidence & confidence

Earnings beat and guidance raise are fresh, material facts that can move the stock today.

Market effects

Sector

Positive for ophthalmology and eye‑care device sector as demand for glaucoma treatments shows strength.

Regional

U.S. market may see modest lift in health‑care stocks.

Global

Limited to U.S. biotech/medical device investors.

Counterpoint

What could challenge this read

Stock may be overvalued at current levels despite the beat; price could stall.

Key entities

  • analyst
    Mizuho

    Raised price target to $225.

  • analyst
    Truist Securities

    Raised price target to $255.

Read at source← All news

StoryGlaukos reports record Q3 sales, beats expectations and lifts 2026‑2027 revenue outlook

Also covered by

5 outlets

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com